AC Immune reported progress in its neurodegenerative disease pipeline with key clinical trial milestones expected in H2 2026, including Phase 2 results for its Parkinson’s drug ACI-7104 and Phase 1 data for its NLRP3 inhibitor. The company triggered a $12 million milestone payment from Takeda after starting a new cohort in its Alzheimer’s ACI-24 trial. With CHF 75.4 million in cash, AC Immune is financially positioned to fund operations into late 2027, supported by partnerships with major pharma firms like Lilly and Takeda. These developments highlight AC Immune’s growing focus on wholly-owned programs and its strong collaboration model.
CEA Industries, identified by the ticker BNC, reportedly holds 515,544 BNB tokens worth over $380 million. This figure reflects the total token balance rather than a recent purchase, with no details on acquisition date or valuation timing. The valuat...
An attacker manipulated the price of TONIC on the Tectonic lending protocol, borrowing $120.4 million across nine markets on the Cronos network. Validators halted the network at block 90,907,150 to prevent further losses and restored the chain to blo...
Tron founder Justin Sun has unstaked a total of 10,000 ETH from the Lido liquid staking protocol since August 26, moving about $12.3 million of that ether to Poloniex, an exchange he supports. While this shows some liquidity being freed up, Sun still...
Starknet has introduced Shieldnet, a new privacy framework called STRK20 that protects transaction details for 45 ERC-20 tokens on its Ethereum Layer 2 network. Using zero-knowledge proofs, Shieldnet encrypts transaction data, hiding sender, receiver...
Microchip Technology reported strong revenue growth and margin recovery in the first quarter of FY2027, driven by accelerating data center demand and growth in aerospace and defense sectors. The company’s valuation is expected to improve significantl...
